Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Yuhan, Luoxin Deal Underscores Asian NSCLC Therapy Needs

Executive Summary

Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.


Related Content

Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer
Should Pharma Be Concerned About Cooling China-Korea Ties?
Korean Tagrisso Launch Builds On Extensive Local Data
Clovis Pulls Plug On Rociletinib On Expected FDA Rejection
Yuhan Joins Immuno-Oncology Wave Via Sorrento JV
Hanmi’s Roll Continues With ZAI China Cancer Deal


Related Companies